Trial Profile

A phase II trial of phenoxodiol [idronoxil] in patients with castrate and non-castrate prostate cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Idronoxil (Primary)
Indications Prostate cancer
Focus Therapeutic Use
Sponsors Lite Strategy; MEI Pharma

Most Recent Events

10 Sep 2025 According to MEI Pharma media release, MEI Pharma has changed its name to Lite Strategy.
21 May 2010 Results will be reported at ASCO, according to a Marshall Edwards medai release.
09 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com